To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negative Solid Tumor

NCT07358377 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: HRS-6209 Capsules and fulvestrant injection

Sponsor

Atridia Pty Ltd.